--- title: "11:54 ET\n\t\t\t\n\t\t\t\n\t\t\t\tLFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm" description: "Rosen Law Firm is reminding investors who purchased LifeMD, Inc. (NASDAQ: LFMD) securities between May 7, 2025, and August 5, 2025, of the October 27, 2025, deadline to lead a securities fraud class a" type: "news" locale: "en" url: "https://longbridge.com/en/news/258241739.md" published_at: "2025-09-21T15:55:32.000Z" --- # 11:54 ET LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm > Rosen Law Firm is reminding investors who purchased LifeMD, Inc. (NASDAQ: LFMD) securities between May 7, 2025, and August 5, 2025, of the October 27, 2025, deadline to lead a securities fraud class action lawsuit. The lawsuit alleges that LifeMD made misleading statements regarding its competitive position and financial guidance, leading to investor damages. Interested parties can join the class action without upfront fees. The Rosen Law Firm has a strong track record in securities litigation and encourages investors to choose qualified counsel. , /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important October 27, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased LifeMD securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the LifeMD class action, go to https://rosenlegal.com/submit-form/?case\_id=43404 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email \[email protected\] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 27, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated LifeMD's competitive position; (2) defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, defendants' statements about LifeMD's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the LifeMD class action, go to https://rosenlegal.com/submit-form/?case\_id=43404 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email \[email protected\] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 \[email protected\] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. ### Related Stocks - [LFMD.US - LifeMD](https://longbridge.com/en/quote/LFMD.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | LifeMD 從 Citizens Bank 獲得了 5000 萬美元的循環信貸額度 | LifeMD Inc. 已從公民銀行獲得了一項 5000 萬美元的循環信貸額度，其中包括 3000 萬美元的承諾資金和 2000 萬美元的可調選項。該信貸額度將於 2029 年 1 月 2 日到期，並提供具有競爭力的資本，且沒有前期費用。L | [Link](https://longbridge.com/en/news/271657692.md) | | Lake Street 繼續維持對 LifeMD（LFMD）的買入評級 | Lake Street 的 Ryan Meyers 對 LifeMD 維持買入評級，目標價為 8.00 美元。這位分析師覆蓋消費週期性行業，平均回報率為-7.0%，成功率為 34.20%。對於 LifeMD 的整體分析師共識為強烈買入，平均 | [Link](https://longbridge.com/en/news/270855288.md) | | Couche-Tard 簡報：蒙特利爾銀行表示公司 “在最近的趨勢中略微加快了有機增長” | Couche-Tard 簡報：BMO 表示公司 “在近期趨勢的基礎上，略微加速了有機增長” | [Link](https://longbridge.com/en/news/275778205.md) | | 19:16 ET Pom 投資者有機會主導對 PomDoctor Ltd.的證券欺詐訴訟 | 羅森律師事務所已宣佈對 PomDoctor Ltd.（納斯達克代碼：POM）投資者提起集體訴訟，涉及購買證券的時間為 2025 年 10 月 9 日至 2025 年 12 月 11 日。投資者可能有權獲得賠償，無需預付費用。訴訟指控 Pom | [Link](https://longbridge.com/en/news/275826590.md) | | 怡安集團｜10-K：2025 財年營收 172 億美元不及預期 | | [Link](https://longbridge.com/en/news/275945420.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.